- Home
- MBRX vs APM Comparison
MBRX vs APM Comparison
Compare MBRX & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBRX
- APM
- Stock Information
- Founded
- MBRX 2015
- APM 2010
- Country
- MBRX United States
- APM United Kingdom
- Employees
- MBRX N/A
- APM N/A
- Industry
- MBRX Biotechnology: Pharmaceutical Preparations
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- MBRX Health Care
- APM Health Care
- Exchange
- MBRX Nasdaq
- APM Nasdaq
- Market Cap
- MBRX 23.5M
- APM 18.9M
- IPO Year
- MBRX 2016
- APM 2018
- Fundamental
- Price
- MBRX $0.44
- APM $1.41
- Analyst Decision
- MBRX Strong Buy
- APM
- Analyst Count
- MBRX 4
- APM 0
- Target Price
- MBRX $5.00
- APM N/A
- AVG Volume (30 Days)
- MBRX 5.2M
- APM 74.2K
- Earning Date
- MBRX 11-12-2025
- APM 12-19-2025
- Dividend Yield
- MBRX N/A
- APM N/A
- EPS Growth
- MBRX N/A
- APM N/A
- EPS
- MBRX N/A
- APM N/A
- Revenue
- MBRX N/A
- APM N/A
- Revenue This Year
- MBRX N/A
- APM N/A
- Revenue Next Year
- MBRX N/A
- APM N/A
- P/E Ratio
- MBRX N/A
- APM N/A
- Revenue Growth
- MBRX N/A
- APM N/A
- 52 Week Low
- MBRX $0.25
- APM $0.46
- 52 Week High
- MBRX $3.65
- APM $7.49
- Technical
- Relative Strength Index (RSI)
- MBRX 42.06
- APM 38.28
- Support Level
- MBRX $0.46
- APM $1.31
- Resistance Level
- MBRX $0.51
- APM $1.48
- Average True Range (ATR)
- MBRX 0.05
- APM 0.06
- MACD
- MBRX -0.00
- APM 0.01
- Stochastic Oscillator
- MBRX 4.81
- APM 34.15
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.